Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Ocrelizumab (Ocrevus)

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)FDA safety resources (3)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Ocrelizumab- Ocrevus™ (opens in a new tab)Original source URL: https://globalrph.com/dilution/ocrelizumab-ocrevus/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/ocrelizumab-ocrevus/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:47:48.419538+00:00
Source location
div.post-content
Packaged content SHA-256
d0a4a83badd677ff651b3a5eb32fd3d34a5d78e679f9781aebc925e27d73cdc1
Original response SHA-256
158af963bd4aa110971c0410cacadd2459d2fb81d9010def9f7ce20837e06056
Source body SHA-256
1062ead52f2ee48f1b94b5986021d077945677bf528f6e9323daf29e9679791d

Ocrelizumab- OCREVUS™ injection
[ Usual Diluents ] [ Standard Dilution ] [ Storage and Stability ]
DESCRIPTION CLINICAL PHARMACOLOGY INDICATIONS AND USAGE
CONTRAINDICATIONS PRECAUTIONS ADVERSE REACTIONS
DOSAGE AND ADMINISTRATION HOW SUPPLIED WARNINGS
PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information / PDF]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

NS

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] Return to article top

[300mg] [250 ml] [See table below]
[600mg] [500 ml] [See table below]
Table 1 Recommended Dose, Infusion Rate, and Infusion Duration for RMS and PPMS
Amount and Volume* Infusion Rate and Duration†
Initial Dose
(two infusions)		 Infusion 1 300 mg in 250 mL
  • Start at 30 mL per hour
  • Increase by 30 mL per hour every 30 minutes
  • Maximum: 180 mL per hour
  • Duration: 2.5 hours or longer
Infusion 2
(2 weeks later)		 300 mg in 250 mL
Subsequent Doses
(one infusion)		 One infusion every 6 months‡ 600 mg in 500 mL
  • Start at 40 mL per hour
  • Increase by 40 mL per hour every 30 minutes
  • Maximum: 200 mL per hour
  • Duration: 3.5 hours or longer
*Solutions of OCREVUS for intravenous infusion are prepared by dilution of the drug product into an infusion bag containing 0.9% Sodium Chloride Injection, to a final drug concentration of approximately 1.2 mg/mL.

†Infusion time may take longer if the infusion is interrupted or slowed [see DOSAGE AND ADMINISTRATION (2.5)].

‡Administer the first Subsequent Dose 6 months after Infusion 1 of the Initial Dose.

Visually inspect for particulate matter and discoloration prior to administration. Do not use the solution if discolored or if the solution contains discrete foreign particulate matter. Do not shake.

Withdraw intended dose and further dilute into an infusion bag containing 0.9% Sodium Chloride Injection, to a final drug concentration of approximately 1.2 mg/mL.

Withdraw 10 mL (300 mg) of OCREVUS and inject into 250 mL
Withdraw 20 mL (600 mg) of OCREVUS and inject into 500 mL
Do not use other diluents to dilute OCREVUS since their use has not been tested. The product contains no preservative and is intended for single use only.

Administration
Administer the diluted infusion solution through a dedicated line using an infusion set with a 0.2 or 0.22 micron in-line filter.

WARNINGS Return to article top

See warnings and precautions below.

DESCRIPTION Return to article top

Description:
Ocrelizumab is a recombinant humanized monoclonal antibody directed against CD20-expressing B-cells. Ocrelizumab is a glycosylated immunoglobulin G1 (IgG1) with a molecular mass of approximately 145 kDa.

OCREVUS (ocrelizumab) Injection for intravenous infusion is a preservative-free, sterile, clear or slightly opalescent, and colorless to pale brown solution supplied in single-dose vials. Each mL of solution contains 30 mg ocrelizumab, glacial acetic acid (0.25 mg), polysorbate 20 (0.2 mg), sodium acetate trihydrate (2.14 mg), and trehalose dihydrate (40 mg) at pH 5.3.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:
The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:
OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis

CONTRAINDICATIONS Return to article top

Contraindications:
Active hepatitis B virus infection
History of life-threatening infusion reaction to OCREVUS

PRECAUTIONS Return to article top

WARNINGS AND PRECAUTIONS:
  1. Infusion reactions: Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs (2.3, 5.1)
  2. Infections: Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion (5.2)
  3. Malignancies: An increased risk of malignancy, including breast cancer, may exist with OCREVUS (5.3)

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:

The most common adverse reactions were:

  • RMS (incidence >/=10% and > REBIF): upper respiratory tract infections and infusion reactions (6.1)
  • PPMS (incidence >/=10% and > placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections (6.1)

    To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide.

DOSAGE AND ADMINISTRATION Return to article top

DOSAGE AND ADMINISTRATION:
2.1 Assessments Prior to First Dose of OCREVUS
Hepatitis B Virus Screening
Prior to initiating OCREVUS, perform Hepatitis B virus (HBV) screening. OCREVUS is contraindicated in patients with active HBV confirmed by positive results for HBsAg and anti-HBV tests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment [see WARNINGS AND PRECAUTIONS (5.2)].

Vaccinations
Because vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation until B-cell repletion, administer all necessary immunizations according to immunization guidelines at least 6 weeks prior to initiation of OCREVUS [see WARNINGS AND PRECAUTIONS (5.2) and CLINICAL PHARMACOLOGY (12.2)].

2.2 Preparation Before Every Infusion
Infection Assessment
Prior to every infusion of OCREVUS, determine whether there is an active infection. In case of active infection, delay infusion of OCREVUS until the infection resolves [see WARNINGS AND PRECAUTIONS (5.2)].

Recommended Premedication
Pre-medicate with 100 mg of methylprednisolone (or an equivalent corticosteroid) administered intravenously approximately 30 minutes prior to each OCREVUS infusion to reduce the frequency and severity of infusion reactions [see WARNINGS AND PRECAUTIONS (5.1)]. Pre-medicate with an antihistamine (e.g., diphenhydramine) approximately 30-60 minutes prior to each OCREVUS infusion to further reduce the frequency and severity of infusion reactions.

The addition of an antipyretic (e.g., acetaminophen) may also be considered.

2.3 Recommended Dosage and Dose Administration
Administer OCREVUS under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.

Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.
Subsequent doses: single 600 mg intravenous infusion every 6 months.
Observe the patient for at least one hour after the completion of the infusion [see WARNINGS AND PRECAUTIONS]. PDF

Table 1 Recommended Dose, Infusion Rate, and Infusion Duration for RMS and PPMS
Amount and Volume* Infusion Rate and Duration†
Initial Dose
(two infusions)		 Infusion 1 300 mg in 250 mL
  • Start at 30 mL per hour
  • Increase by 30 mL per hour every 30 minutes
  • Maximum: 180 mL per hour
  • Duration: 2.5 hours or longer
Infusion 2
(2 weeks later)		 300 mg in 250 mL
Subsequent Doses
(one infusion)		 One infusion every 6 months‡ 600 mg in 500 mL
  • Start at 40 mL per hour
  • Increase by 40 mL per hour every 30 minutes
  • Maximum: 200 mL per hour
  • Duration: 3.5 hours or longer
*Solutions of OCREVUS for intravenous infusion are prepared by dilution of the drug product into an infusion bag containing 0.9% Sodium Chloride Injection, to a final drug concentration of approximately 1.2 mg/mL.

†Infusion time may take longer if the infusion is interrupted or slowed [see DOSAGE AND ADMINISTRATION (2.5)].

‡Administer the first Subsequent Dose 6 months after Infusion 1 of the Initial Dose.

2.4 Delayed or Missed Doses
If a planned infusion of OCREVUS is missed, administer OCREVUS as soon as possible; do not wait until the next scheduled dose. Reset the dose schedule to administer the next sequential dose 6 months after the missed dose is administered. Doses of OCREVUS must be separated by at least 5 months [see DOSAGE AND ADMINISTRATION (2.3)].

2.5 Dose Modifications Because of Infusion Reactions
Dose modifications in response to infusion reactions depends on the severity.

Life-threatening Infusion Reactions
Immediately stop and permanently discontinue OCREVUS if there are signs of a life-threatening or disabling infusion reaction [see WARNINGS AND PRECAUTIONS (5.1)]. Provide appropriate supportive treatment.

Severe Infusion Reactions
Immediately interrupt the infusion and administer appropriate supportive treatment, as necessary [see WARNINGS AND PRECAUTIONS (5.1)]. Restart the infusion only after all symptoms have resolved. When restarting, begin at half of the infusion rate at the time of onset of the infusion reaction [see DOSAGE AND ADMINISTRATION (2.2)]. If this rate is tolerated, increase the rate as described in TABLE 1. This change in rate will increase the total duration of the infusion but not the total dose.

Mild to Moderate Infusion Reactions
Reduce the infusion rate to half the rate at the onset of the infusion reaction and maintain the reduced rate for at least 30 minutes [see WARNINGS AND PRECAUTIONS (5.1)]. If this rate is tolerated, increase the rate as described in TABLE 1. This change in rate will increase the total duration of the infusion but not the total dose.

2.6 Preparation and Storage of the Dilute Solution for Infusion
Preparation
OCREVUS must be prepared by a healthcare professional using aseptic technique.

Visually inspect for particulate matter and discoloration prior to administration. Do not use the solution if discolored or if the solution contains discrete foreign particulate matter. Do not shake.

Withdraw intended dose and further dilute into an infusion bag containing 0.9% Sodium Chloride Injection, to a final drug concentration of approximately 1.2 mg/mL.

Withdraw 10 mL (300 mg) of OCREVUS and inject into 250 mL
Withdraw 20 mL (600 mg) of OCREVUS and inject into 500 mL
Do not use other diluents to dilute OCREVUS since their use has not been tested. The product contains no preservative and is intended for single use only.

Administration
Administer the diluted infusion solution through a dedicated line using an infusion set with a 0.2 or 0.22 micron in-line filter.

HOW SUPPLIED Return to article top

DOSAGE FORMS AND STRENGTHS:
Injection: 300 mg/10 mL (30 mg/mL) in a single-dose vial.

Storage and Stability Return to article top

OCREVUS (ocrelizumab) injection is a preservative-free, sterile, clear or slightly opalescent, and colorless to pale brown solution supplied as a carton containing one 300 mg/10 mL (30 mg/mL) single-dose vial (NDC 50242-150-01).

Store OCREVUS vials at 2°C-8°C (36°F-46°F) in the outer carton to protect from light. Do not freeze or shake.

Storage of Infusion Solution
Prior to the start of the intravenous infusion, the content of the infusion bag should be at room temperature.

Use the prepared infusion solution immediately. If not used immediately, store up to 24 hours in the refrigerator at 2°C-8°C (36°F-46°F) and 8 hours at room temperature up to 25°C (77°F), which includes infusion time. In the event an intravenous infusion cannot be completed the same day, discard the remaining solution.

No incompatibilities between OCREVUS and polyvinyl chloride (PVC) or polyolefin (PO) bags and intravenous (IV) administration sets have been observed.
Disclaimer

Open this historical article on its own

FDA safety resources for this medication (3)
  • FDA AEMS Q1 2026: Pneumocystis jirovecii infection - no action needed at that time (status 2026-06-04) (opens in a new tab)
    Dated FDA status and source scope

    Potential-signal tables are safety-review resources. Inclusion alone does not establish causality or a treatment change.

    FDA table status date: 2026-06-04

    Status in that table: FDA determined that no action was needed at the time based on available information.

    Exact table location: January - March 2026 safety table, data row 5 (header excluded): Product Name / Product Class = Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Ocrevus (ocrelizumab) injection Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection; Signal = Pneumocystis jirovecii infection; Additional Information (as of 2026-06-04)

    Scope: Matches the expressly listed product/ingredient for safety-resource navigation only. It does not reconcile a stocked manufacturer, package NDC, lot or full monograph and does not establish causality. The match uses the separately listed Ocrevus product, not Ocrevus Zunovo; do not import the coformulated product or its route into the IV record.

    Interpretation: No action needed at that time is not a declaration that the product cannot cause the event, that all infection risk is absent, or that existing labeling precautions should be removed.

  • FDA AEMS Q2 2026: Pneumonitis - evaluating regulatory action (status 2026-09-04) (opens in a new tab)
    Dated FDA status and source scope

    Potential-signal tables are safety-review resources. Inclusion alone does not establish causality or a treatment change.

    FDA table status date: 2026-09-04

    Status in that table: FDA is evaluating the need for regulatory action.

    Exact table location: April - June 2026 safety table, data row 3 (header excluded): Product Name / Product Class = Anti-CD20 monoclonal antibodies Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Ocrevus (ocrelizumab) injection Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection; Signal = Pneumonitis; Additional Information (as of 2026-09-04)

    Scope: Matches the expressly listed product/ingredient for safety-resource navigation only. It does not reconcile a stocked manufacturer, package NDC, lot or full monograph and does not establish causality. The match uses the separately listed Ocrevus product, not Ocrevus Zunovo; do not import the coformulated product or its route into the IV record.

  • FDA AEMS Q2 2026: Serum sickness - evaluating regulatory action (status 2026-09-04) (opens in a new tab)
    Dated FDA status and source scope

    Potential-signal tables are safety-review resources. Inclusion alone does not establish causality or a treatment change.

    FDA table status date: 2026-09-04

    Status in that table: FDA is evaluating the need for regulatory action.

    Exact table location: April - June 2026 safety table, data row 4 (header excluded): Product Name / Product Class = Anti-CD20 monoclonal antibodies Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Ocrevus (ocrelizumab) injection Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection; Signal = Serum sickness; Additional Information (as of 2026-09-04)

    Scope: Matches the expressly listed product/ingredient for safety-resource navigation only. It does not reconcile a stocked manufacturer, package NDC, lot or full monograph and does not establish causality. The match uses the separately listed Ocrevus product, not Ocrevus Zunovo; do not import the coformulated product or its route into the IV record.

Read the linked communication and current prescribing information before use. Resource dates and affected product scopes differ; a listed resource is not a full monograph or a lot-specific clearance.

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ocrelizumab-ocrevus
      Source IDH51-6750626598F51B171A54A389
      Generic name
      Ocrelizumab (Ocrevus)
      Source IDH51-6546282E68D9E117A46273B5
      Class
      Biologics and immunotherapy
      Source IDH51-9E7702E0B1A35782DB103158
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-E7F685D83324A84E5BA2BD40
      Primary uses
      1. The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic.
        Source IDH51-135E29E471242EA2937BF85D
      Mechanism
      Binds CD20 on B lymphocytes and produces immune-mediated B-cell depletion.
      Source IDH51-000380F6B0FD6763843724C6
      Mechanism level
      drug_specific
      Source IDH51-78F9051A9733D426741542B2
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-C30924F87AB22D0C860C7307
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-48D0816207189330CABAEC35
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-4B49DBB55332AF13393AF243
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-50C4A6FEE2AB23C78C70D0DC
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-AA87279569873278D43CF45E
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-2DC7E808370ED2033589D318
      Legacy title
      Ocrelizumab (Ocrevus)
      Source IDH51-5D13284251515A381B103865
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-E24C9AD077C08CFB228E78FD
      Search text
      Ocrelizumab (Ocrevus) Biologics and immunotherapy Legacy GlobalRPh directory entry The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic. Binds CD20 on B lymphocytes and produces immune-mediated B-cell depletion. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-DF49383B50C5F79923A35A29
      Official access mode
      none
      Source IDH51-7E8AAE5F412328425521D03E
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-A84E73F150FD7D1A9218F757

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-EF8DDACA659288F69F232E60
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-51592C81310C79B1077B2B9C
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-4A436FBF6D835F5FA2C98B4C

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-FADB757E6052564542BF564F

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-059B2E1E4A96877C276B534A
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      ocrelizumab-ocrevus
      Source IDH51-88E0B7B5509EE2D999B2EC3A
      Legacy title
      Ocrelizumab (Ocrevus)
      Source IDH51-CBD016B273867FCE2BAB63EF
      Generic name
      Ocrelizumab (Ocrevus)
      Source IDH51-93A37D4A05F94D7958D460E6
      Class
      Biologics and immunotherapy
      Source IDH51-8162BA267897F9217D9BC205
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-AE9FC4B414F3EF46F279411C
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-A218E511EF2339C639366177
      Populations
      1. Population not yet normalized
        Source IDH51-A3CD7FD19C88420AF4FC87A5
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-629884BCCCE88677F71C3E5C
      High alert
      false
      Source IDH51-D21B39C3BE87BC07BE52D24F
      Hazardous
      false
      Source IDH51-CAA304DADA286C1CD40AE5BC
      Status
      Legacy migration
      Source IDH51-4D9B2ACEB2F84DC04B073AEA
      Version added
      Legacy
      Source IDH51-C171DF2CF661D156C2F69ED2
      Sources
      LabelUrlKind
      Source IDH51-3B9D618E70E6F7B2690A881A
      GlobalRPh legacy IV dilution monograph
      Source IDH51-84F415EAC208BA7D65A441FA
      		legacy:auto
      Source IDH51-FBDE78BB48C0D78304113552
      		Legacy
      Source IDH51-BF0A99EB70D0386F8FB8AB26
      Clinical release verification
      Audit version
      3.4
      Source IDH51-7B9D774018E661C5C321AFBE
      Audited on
      2026-08-30
      Source IDH51-C67CDBF5F47D6B923F42CF42
      Level
      red
      Source IDH51-A716992D41E8D876447631FC
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-E665F4716F72A840EC977BCA
      Exact current label candidate
      false
      Source IDH51-7FBF9F2508DFF3F479EE9EE7
      Reference url count
      0
      Source IDH51-FCC5E10690A973451E466E28
      Broken reference count
      0
      Source IDH51-1DD5B7AC2CEECF0809A04861
      Point of use confirmation required
      true
      Source IDH51-4F53982F6325C380222A1629
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-3E8F7D0F78C5771AA87D9569

      Dosing source fields

      Id
      ocrelizumab-ocrevus
      Source IDH51-A279C20CD60D8DB8BC8CB139
      Generic name
      Ocrelizumab (Ocrevus)
      Source IDH51-98CA154FD1F4102A37D61A35
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-FBCCD60CD63523708ECF32FC
      Package insert
      Query name
      Ocrelizumab
      Source IDH51-DE52B60DCBB678BED48ECF52
      Product and route must match
      true
      Source IDH51-3F91333DF8F42917AA7EC582
      Live current label enabled
      false
      Source IDH51-14D24C13A515142F3EB56387
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-9C6C882C1DB51D4E71F8CE88
      Direct official label access enabled
      true
      Source IDH51-601C940BD52B56AF36013D63
      Outbound server request required
      false
      Source IDH51-C303E539E04DF939A8E271F9
      Local summary status
      not_bundled
      Source IDH51-F4DAE5D9240FB161CA2F2953
      Clinical review
      Locally normalized
      false
      Source IDH51-283E053D48C571E77A7E24E6
      Reviewed
      2026-08-29
      Source IDH51-76D2785519F6FB78B4E7B724
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-73B2D9387010DB3C06D22A11
      Clinical release verification
      Audit version
      3.4
      Source IDH51-AA4D63212FDA7F5E565F2BD9
      Audited on
      2026-08-30
      Source IDH51-AFE7F565AE998751E9C2ADB2
      Level
      red
      Source IDH51-1DDDF1904DA2507E80091168
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-FA469B68FAC4DC1D1DF84B6F
      Exact current label candidate
      false
      Source IDH51-7FEB10813637DB96A0F783DA
      Reference url count
      0
      Source IDH51-A9CF1D66D813133CC747C4A3
      Broken reference count
      0
      Source IDH51-094A53F7B28811CBA7E5FAE4
      Point of use confirmation required
      true
      Source IDH51-49ED3EA7673E4E11B59D21BB
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-EE11299EB309D5E3B5C129EF
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ocrelizumab-ocrevus
      Source IDH51-6C43AA32CE0CA247E9C346DC
      Name
      Ocrelizumab (Ocrevus)
      Source IDH51-73B431C93F94B60210A86D0C
      Therapeutic class
      Biologics and immunotherapy
      Source IDH51-9CC7D6C9B5D55B5A3A424D2C
      Review version
      3.1
      Source IDH51-5B5BD26E1806A2AC4B81428B
      Review date
      2026-08-30
      Source IDH51-FE48CBB2539837837F92557A
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-3BE1DEC988026C341945FAE2
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-60CC55D3B633EFB5D0A1FC41
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-232073C8329DA96E6071B5E6
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-5D06296339C8FB306E67F4DD
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-7464DFAC3DFBFB44E8F0628C
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-5EE928079499B5999B775684
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-ACA50507CBA95E0FD5AC8FCF
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-BE1B2F9563B84F9BCDBE6AB3
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-9648DD051FA5545634F9C5B1
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-C7ED901825040783626FF438
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-85A0C8D03545922234A4C111
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-2F700C938AED3E5E49439E53
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-5C075B8A50D252B8DE5CD3C6
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-33F8A9AEB58EF494E2426EB5
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-9C9FDACADBDF5817CE988BF3
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-3F55E1754714F266C50008DF
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-8D3117613526DC8AD404868F
      Adult dosing range
      Primary
      not_found
      Source IDH51-0A113649BB2C49D85A805C47
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-8175900217C654904FF6F9E7
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-59CCD96A91C99A652AEF5284
      Infusion time
      Primary
      not_found
      Source IDH51-A5F7744A5E789773E0F61448
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-700A2BC1CC8A546EE675BF41
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-D9927CD314A1DE361987B53C
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-138700BDD34981D1DB89F433
      Guide generation allowed
      false
      Source IDH51-6CC27254CB1DDCECF9039465
      Pediatric
      Applicability
      not_established
      Source IDH51-6625E057926EF51116FBD783
      Guide generation allowed
      false
      Source IDH51-58C6B5341424E5B4DB7475FB
      Neonatal
      Applicability
      not_established
      Source IDH51-8CC7F6481C7E367771754845
      Guide generation allowed
      false
      Source IDH51-30D29E70AE8CAE02AAE79269
      Route presence
      Structured dilution
      false
      Source IDH51-63E129864726FCF06EEB3373
      Iv push
      false
      Source IDH51-3468E83E3A4073E7FFF0F00B
      Continuous infusion
      false
      Source IDH51-65436F37E9A909BC7B35CB83
      Pediatric source
      false
      Source IDH51-9F7C2DADBFC8916BC24FB8C8
      Neonatal source
      false
      Source IDH51-90E45F75241E92AE2F7DF40C
      Legacy reference
      Status
      not_available
      Source IDH51-C5C6E8C0CAB4E012382073CB
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-D649293E71853613FBB4B33F
      Source files
      1. catalog.json
        Source IDH51-95ABF2EA899E29611C1E9FA7
      2. dosing.json
        Source IDH51-E605FDDFD49425B50C2A4DFC
      3. legacy-map.json
        Source IDH51-46E36D653105557F9261CDEB
      4. review-queue.json
        Source IDH51-07911486875CA1FA7009CA46
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-765CD14CA24B3886E05BFD37
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-88E0B7B5509EE2D999B2EC3Acatalog.json
      /records/181/id      		Historical; current review incomplete
      H51-CBD016B273867FCE2BAB63EFcatalog.json
      /records/181/legacy_title      		Historical; current review incomplete
      H51-93A37D4A05F94D7958D460E6catalog.json
      /records/181/generic_name      		Historical; current review incomplete
      H51-8162BA267897F9217D9BC205catalog.json
      /records/181/class      		Historical; current review incomplete
      H51-AE9FC4B414F3EF46F279411Ccatalog.json
      /records/181/subclass      		Historical; current review incomplete
      H51-A218E511EF2339C639366177catalog.json
      /records/181/summary      		Historical; current review incomplete
      H51-FADB757E6052564542BF564Fcatalog.json
      /records/181/warnings/0      		Historical; current review incomplete
      H51-059B2E1E4A96877C276B534Acatalog.json
      /records/181/stability_notes/0      		Historical; current review incomplete
      H51-A3CD7FD19C88420AF4FC87A5catalog.json
      /records/181/populations/0      		Historical; current review incomplete
      H51-629884BCCCE88677F71C3E5Ccatalog.json
      /records/181/evidence_tier      		Historical; current review incomplete
      H51-D21B39C3BE87BC07BE52D24Fcatalog.json
      /records/181/high_alert      		Historical; current review incomplete
      H51-CAA304DADA286C1CD40AE5BCcatalog.json
      /records/181/hazardous      		Historical; current review incomplete
      H51-4D9B2ACEB2F84DC04B073AEAcatalog.json
      /records/181/status      		Historical; current review incomplete
      H51-E430AAB1F65DD750A12EF81Bcatalog.json
      /records/181/reviewed      		Historical; current review incomplete
      H51-C171DF2CF661D156C2F69ED2catalog.json
      /records/181/version_added      		Historical; current review incomplete
      H51-3B9D618E70E6F7B2690A881Acatalog.json
      /records/181/sources/0      		Historical; current review incomplete
      H51-84F415EAC208BA7D65A441FAcatalog.json
      /records/181/sources/0/label      		Historical; current review incomplete
      H51-FBDE78BB48C0D78304113552catalog.json
      /records/181/sources/0/url      		Historical; current review incomplete
      H51-BF0A99EB70D0386F8FB8AB26catalog.json
      /records/181/sources/0/kind      		Historical; current review incomplete
      H51-7B9D774018E661C5C321AFBEcatalog.json
      /records/181/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-C67CDBF5F47D6B923F42CF42catalog.json
      /records/181/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-A716992D41E8D876447631FCcatalog.json
      /records/181/clinical_release_verification/level      		Historical; current review incomplete
      H51-E665F4716F72A840EC977BCAcatalog.json
      /records/181/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-7FBF9F2508DFF3F479EE9EE7catalog.json
      /records/181/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-32330BA6175772DD394B7070catalog.json
      /records/181/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-4ABDE55858029493823CACF9catalog.json
      /records/181/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-B6575B5C3C10950A0B4C868Fcatalog.json
      /records/181/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-FCC5E10690A973451E466E28catalog.json
      /records/181/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-1DD5B7AC2CEECF0809A04861catalog.json
      /records/181/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-4F53982F6325C380222A1629catalog.json
      /records/181/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-3E8F7D0F78C5771AA87D9569catalog.json
      /records/181/clinical_release_verification/note      		Historical; current review incomplete
      H51-E3C3C4BCFD670E0C9D867512catalog.json
      /records/181/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-A279C20CD60D8DB8BC8CB139dosing.json
      /records/181/id      		Historical; current review incomplete
      H51-98CA154FD1F4102A37D61A35dosing.json
      /records/181/generic_name      		Historical; current review incomplete
      H51-FBCCD60CD63523708ECF32FCdosing.json
      /records/181/coverage_status      		Historical; current review incomplete
      H51-DE52B60DCBB678BED48ECF52dosing.json
      /records/181/package_insert/query_name      		Historical; current review incomplete
      H51-2927B8CD575B44540D65B9C5dosing.json
      /records/181/package_insert/preferred_setid      		Historical; current review incomplete
      H51-3F91333DF8F42917AA7EC582dosing.json
      /records/181/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-14D24C13A515142F3EB56387dosing.json
      /records/181/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-9C6C882C1DB51D4E71F8CE88dosing.json
      /records/181/package_insert/source_priority      		Historical; current review incomplete
      H51-601C940BD52B56AF36013D63dosing.json
      /records/181/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-C303E539E04DF939A8E271F9dosing.json
      /records/181/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-F4DAE5D9240FB161CA2F2953dosing.json
      /records/181/package_insert/local_summary_status      		Historical; current review incomplete
      H51-EF8DDACA659288F69F232E60dosing.json
      /records/181/renal/classification      		Historical; current review incomplete
      H51-51592C81310C79B1077B2B9Cdosing.json
      /records/181/renal/summary      		Historical; current review incomplete
      H51-4A436FBF6D835F5FA2C98B4Cdosing.json
      /records/181/renal/method_note      		Historical; current review incomplete
      H51-283E053D48C571E77A7E24E6dosing.json
      /records/181/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-76D2785519F6FB78B4E7B724dosing.json
      /records/181/clinical_review/reviewed      		Historical; current review incomplete
      H51-73B2D9387010DB3C06D22A11dosing.json
      /records/181/clinical_review/status      		Historical; current review incomplete
      H51-AA4D63212FDA7F5E565F2BD9dosing.json
      /records/181/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-AFE7F565AE998751E9C2ADB2dosing.json
      /records/181/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-1DDDF1904DA2507E80091168dosing.json
      /records/181/clinical_release_verification/level      		Historical; current review incomplete
      H51-FA469B68FAC4DC1D1DF84B6Fdosing.json
      /records/181/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-7FEB10813637DB96A0F783DAdosing.json
      /records/181/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-C1176B55046E6B3E4C776814dosing.json
      /records/181/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-4EE2AB0AFE95F08B07288FF9dosing.json
      /records/181/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-F52B43A4961023E532CDF3E5dosing.json
      /records/181/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-A9CF1D66D813133CC747C4A3dosing.json
      /records/181/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-094A53F7B28811CBA7E5FAE4dosing.json
      /records/181/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-49ED3EA7673E4E11B59D21BBdosing.json
      /records/181/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-EE11299EB309D5E3B5C129EFdosing.json
      /records/181/clinical_release_verification/note      		Historical; current review incomplete
      H51-0FD1821674E9DCB1E3244E69dosing.json
      /records/181/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-6750626598F51B171A54A389first-look-v5.1.json
      /records/181/id      		Historical; current review incomplete
      H51-6546282E68D9E117A46273B5first-look-v5.1.json
      /records/181/generic_name      		Historical; current review incomplete
      H51-9E7702E0B1A35782DB103158first-look-v5.1.json
      /records/181/class      		Historical; current review incomplete
      H51-E7F685D83324A84E5BA2BD40first-look-v5.1.json
      /records/181/subclass      		Historical; current review incomplete
      H51-135E29E471242EA2937BF85Dfirst-look-v5.1.json
      /records/181/primary_uses/0      		Historical; current review incomplete
      H51-000380F6B0FD6763843724C6first-look-v5.1.json
      /records/181/mechanism      		Historical; current review incomplete
      H51-78F9051A9733D426741542B2first-look-v5.1.json
      /records/181/mechanism_level      		Historical; current review incomplete
      H51-C30924F87AB22D0C860C7307first-look-v5.1.json
      /records/181/basic_dosing_orientation      		Historical; current review incomplete
      H51-48D0816207189330CABAEC35first-look-v5.1.json
      /records/181/administration_orientation      		Historical; current review incomplete
      H51-4B49DBB55332AF13393AF243first-look-v5.1.json
      /records/181/renal_and_population_orientation      		Historical; current review incomplete
      H51-50C4A6FEE2AB23C78C70D0DCfirst-look-v5.1.json
      /records/181/key_safety_orientation/0      		Historical; current review incomplete
      H51-AA87279569873278D43CF45Efirst-look-v5.1.json
      /records/181/coverage_path      		Historical; current review incomplete
      H51-2DC7E808370ED2033589D318first-look-v5.1.json
      /records/181/coverage_path_label      		Historical; current review incomplete
      H51-2DD2F21F70EF2D38B580CD31first-look-v5.1.json
      /records/181/official_label_url      		Historical; current review incomplete
      H51-5D13284251515A381B103865first-look-v5.1.json
      /records/181/legacy_title      		Historical; current review incomplete
      H51-E24C9AD077C08CFB228E78FDfirst-look-v5.1.json
      /records/181/review_note      		Historical; current review incomplete
      H51-DF49383B50C5F79923A35A29first-look-v5.1.json
      /records/181/search_text      		Historical; current review incomplete
      H51-2C95B9923CFA0CBBB57E6C49first-look-v5.1.json
      /records/181/official_search_url      		Historical; current review incomplete
      H51-7E8AAE5F412328425521D03Efirst-look-v5.1.json
      /records/181/official_access_mode      		Historical; current review incomplete
      H51-84124B5F505E2F0A9030B43Bfirst-look-v5.1.json
      /records/181/official_access_url      		Historical; current review incomplete
      H51-6080511903432D42F8DEDE83first-look-v5.1.json
      /records/181/official_search_query      		Historical; current review incomplete
      H51-A84E73F150FD7D1A9218F757first-look-v5.1.json
      /records/181/official_access_reason      		Historical; current review incomplete
      H51-6C43AA32CE0CA247E9C346DCpreparation-assessments-v3.8.json
      /181/id      		Historical; current review incomplete
      H51-73B431C93F94B60210A86D0Cpreparation-assessments-v3.8.json
      /181/name      		Historical; current review incomplete
      H51-44749F0FDA26E1A2958106DApreparation-assessments-v3.8.json
      /181/brands      		Historical; current review incomplete
      H51-9CC7D6C9B5D55B5A3A424D2Cpreparation-assessments-v3.8.json
      /181/therapeutic_class      		Historical; current review incomplete
      H51-5B5BD26E1806A2AC4B81428Bpreparation-assessments-v3.8.json
      /181/review_version      		Historical; current review incomplete
      H51-FE48CBB2539837837F92557Apreparation-assessments-v3.8.json
      /181/review_date      		Historical; current review incomplete
      H51-3BE1DEC988026C341945FAE2preparation-assessments-v3.8.json
      /181/release_status      		Historical; current review incomplete
      H51-60CC55D3B633EFB5D0A1FC41preparation-assessments-v3.8.json
      /181/market_status/status      		Historical; current review incomplete
      H51-232073C8329DA96E6071B5E6preparation-assessments-v3.8.json
      /181/market_status/basis      		Historical; current review incomplete
      H51-5D06296339C8FB306E67F4DDpreparation-assessments-v3.8.json
      /181/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-7464DFAC3DFBFB44E8F0628Cpreparation-assessments-v3.8.json
      /181/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-5EE928079499B5999B775684preparation-assessments-v3.8.json
      /181/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-ACA50507CBA95E0FD5AC8FCFpreparation-assessments-v3.8.json
      /181/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-BE1B2F9563B84F9BCDBE6AB3preparation-assessments-v3.8.json
      /181/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-9648DD051FA5545634F9C5B1preparation-assessments-v3.8.json
      /181/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-C7ED901825040783626FF438preparation-assessments-v3.8.json
      /181/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-85A0C8D03545922234A4C111preparation-assessments-v3.8.json
      /181/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-2F700C938AED3E5E49439E53preparation-assessments-v3.8.json
      /181/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-5AE24592B7C19C7E021E68B1preparation-assessments-v3.8.json
      /181/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-FAE2FB4659C4510C72BAEBFCpreparation-assessments-v3.8.json
      /181/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-8F8CDE81C7BD527C1B38EE0Epreparation-assessments-v3.8.json
      /181/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-39E0ADB7BEA421424427A4F1preparation-assessments-v3.8.json
      /181/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-5C075B8A50D252B8DE5CD3C6preparation-assessments-v3.8.json
      /181/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-FC53DA97F07F05C11F3E426Apreparation-assessments-v3.8.json
      /181/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-33F8A9AEB58EF494E2426EB5preparation-assessments-v3.8.json
      /181/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-9C9FDACADBDF5817CE988BF3preparation-assessments-v3.8.json
      /181/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-3F55E1754714F266C50008DFpreparation-assessments-v3.8.json
      /181/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-8D3117613526DC8AD404868Fpreparation-assessments-v3.8.json
      /181/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-0A113649BB2C49D85A805C47preparation-assessments-v3.8.json
      /181/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-8175900217C654904FF6F9E7preparation-assessments-v3.8.json
      /181/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-59CCD96A91C99A652AEF5284preparation-assessments-v3.8.json
      /181/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-A5F7744A5E789773E0F61448preparation-assessments-v3.8.json
      /181/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-700A2BC1CC8A546EE675BF41preparation-assessments-v3.8.json
      /181/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-D9927CD314A1DE361987B53Cpreparation-assessments-v3.8.json
      /181/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-138700BDD34981D1DB89F433preparation-assessments-v3.8.json
      /181/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-6CC27254CB1DDCECF9039465preparation-assessments-v3.8.json
      /181/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-6625E057926EF51116FBD783preparation-assessments-v3.8.json
      /181/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-58C6B5341424E5B4DB7475FBpreparation-assessments-v3.8.json
      /181/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-8CC7F6481C7E367771754845preparation-assessments-v3.8.json
      /181/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-30D29E70AE8CAE02AAE79269preparation-assessments-v3.8.json
      /181/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-63E129864726FCF06EEB3373preparation-assessments-v3.8.json
      /181/route_presence/structured_dilution      		Historical; current review incomplete
      H51-3468E83E3A4073E7FFF0F00Bpreparation-assessments-v3.8.json
      /181/route_presence/iv_push      		Historical; current review incomplete
      H51-65436F37E9A909BC7B35CB83preparation-assessments-v3.8.json
      /181/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-9F7C2DADBFC8916BC24FB8C8preparation-assessments-v3.8.json
      /181/route_presence/pediatric_source      		Historical; current review incomplete
      H51-90E45F75241E92AE2F7DF40Cpreparation-assessments-v3.8.json
      /181/route_presence/neonatal_source      		Historical; current review incomplete
      H51-C5C6E8C0CAB4E012382073CBpreparation-assessments-v3.8.json
      /181/legacy_reference/status      		Historical; current review incomplete
      H51-D649293E71853613FBB4B33Fpreparation-assessments-v3.8.json
      /181/label_resolution/status      		Historical; current review incomplete
      H51-95ABF2EA899E29611C1E9FA7preparation-assessments-v3.8.json
      /181/source_files/0      		Historical; current review incomplete
      H51-E605FDDFD49425B50C2A4DFCpreparation-assessments-v3.8.json
      /181/source_files/1      		Historical; current review incomplete
      H51-46E36D653105557F9261CDEBpreparation-assessments-v3.8.json
      /181/source_files/2      		Historical; current review incomplete
      H51-07911486875CA1FA7009CA46preparation-assessments-v3.8.json
      /181/source_files/3      		Historical; current review incomplete
      H51-765CD14CA24B3886E05BFD37preparation-assessments-v3.8.json
      /181/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top